Questcor Pharmaceuticals, Inc. (Questcor) markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (MS), and the treatment of nephrotic syndrome. H.P. Acthar Gel (Acthar) is not indicated for, but is also used in treating patients with infantile spasms (IS). The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. As of December 31, 2008, Acthar was approved in the United States for the treatment of exacerbations associated with MS, nephrotic syndrome and many other conditions with an inflammatory component.
At Questcor, we are a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Our efforts are currently focused on the fields of neurology and nephrology, areas of medicine which have significant unmet medical needs.
Our Business Strategy
Our highly experienced Sales and Marketing teams are presently focused on increasing the usage of our primary marketed product, Acthar, among specialists who treat patients with multiple sclerosis, infantile spasms and nephrotic syndrome. In addition, our Medical Affairs personnel are working with leading researchers to explore promising additional uses for this important product in a variety of other conditions.
How we implement our business strategy:
- Increase revenues through sales and marketing activities targeted to physicians who treat patients with serious, difficult-to-treat medical conditions.
- Leverage our primary product, Acthar, through investing in clinical research in patient populations where there is high unmet medical need and potential benefits from Acthar therapy.
- Actively give back to our patients and physician communities by providing state-of-the-art patient assistance programs, as well as financial support for innovative medical research at major academic institutions.
Events and Presentations: http://ir.questcor.com/events.cfm
Upcoming Events: Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011